An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients

大麻素替代疗法 (Sativex®) 的随机对照试验，用于治疗难治性大麻依赖患者

• 批准号: nhmrc : GNT1088902
• 负责人: A/Pr David Allsop
• 金额: $ 50.86万
• 依托单位: University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/an-rct-cannabinoid-dependent-patients/1345755
• 关键词: RCT; cannabinoid; replacement; therapy; Sativex

This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.

该项目是有史以来第一个门诊随机对照试验，旨在测试药物大麻素Sativex能否安全、经济有效地为寻求慢性大麻依赖治疗的患者提供更好的治疗结果。Sativex是一种含有等量四氢大麻酚和大麻二酚的口腔喷雾剂，似乎比非法大麻或单独合成四氢大麻酚更安全。因此，Sativex可能导致较低的精神不良事件发生率和增加大麻戒断率。